A novel radioguided surgery technique exploiting Î²- decays by Camillocci, E. Solfaroli et al.
A novel radioguided surgery technique
exploiting b2 decays
E. Solfaroli Camillocci1, G. Baroni2, F. Bellini3,4, V. Bocci4, F. Collamati3,4, M. Cremonesi5, E. De Lucia10,
P. Ferroli6, S. Fiore4,7, C. M. Grana13, M. Marafini4,8, I. Mattei9,10, S. Morganti4, G. Paganelli12,
V. Patera4,11, L. Piersanti4,11, L. Recchia4, A. Russomando1,3,4, M. Schiariti6, A. Sarti10,11, A. Sciubba4,11,
C. Voena4 & R. Faccini3,4
1Center for Life Nano Science@Sapienza, Istituto Italiano di Tecnologia, Roma, Italy, 2Dip. Elettronica, Informazione e
Bioingegneria, Politecnico di Milano, Italy, 3Dip. Fisica, Sapienza Univ. di Roma, Roma, Italy, 4INFN Sezione di Roma, Roma, Italy,
5Div. Fisica Medica, Istituto Europeo di Oncologia, Milano, Italy, 6Fondazione Istituto Neurologico Carlo Besta, Milano, Italy,
7ENEA UTTMAT-IRR, Casaccia R.C., Roma, Italy, 8Museo Storico della Fisica e Centro Studi e Ricerche ‘E. Fermi’, Roma, Italy,
9Dipartimento di Matematica e Fisica, Universita` Roma Tre, Roma, Italy, 10Laboratori Nazionali di Frascati dell’INFN, Frascati, Italy,
11Dip. Scienze di Base e Applicate per l’Ingegneria, Sapienza Univ. di Roma, Roma, Italy, 12Department of Nuclear Medicine and
Radiometabolic Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRST-IRCCS, Meldola, Italy, 13Div. Medicina
Nucleare, Istituto Europeo di Oncologia, Milano, Italy.
The background induced by the high penetration power of the radiation is the main limiting factor of the
current radio-guided surgery (RGS). To partially mitigate it, a RGS with b1-emitting radio-tracers has been
suggested in literature. Here we propose the use of b2-emitting radio-tracers and b2 probes and discuss the
advantage of this method with respect to the previously explored ones: the electron low penetration power
allows for simple and versatile probes and could extend RGS to tumours for which background originating
from nearby healthy tissue makes probes less effective. We developed a b2 probe prototype and studied its
performances on phantoms. By means of a detailed simulation we have also extrapolated the results to
estimate the performances in a realistic case of meningioma, pathology which is going to be our first in-vivo
test case. A good sensitivity to residuals down to 0.1 ml can be reached within 1 s with an administered
activity smaller than those for PET-scans thus making the radiation exposure to medical personnel negligible.
T
he radio-guided surgery (RGS) is a surgical technique, first developed some 60 years ago, that enables the
surgeon to evaluate the completeness of the tumoural lesion resection, while minimizing the amount of
healthy tissue removed1. The impact of the RGS on the surgical management of cancer patients includes
providing the surgeon with vital and real-time information regarding the location and the extent of the lesion, as
well as assessing surgical resection margins. The technique (see Fig. 1) makes use of a radio-labelled tracer,
preferentially taken up by the tumour to mark the cancerous tissue from the healthy organs, and a probe (for a
review see2), sensitive to the emission released by the tracer, to identify in real time the targeted tumour loci. The
radio-pharmaceutical is administered to the patient just before the surgery.
Current clinical applications of the RGS are: radio-immuno-guided surgery (RIGS) for colon cancer, complete
sentinel-node mapping for malignant melanoma and breast cancer, and detection of parathyroid adenoma and
bone tumours (such as osteoid osteoma).
Established methods make use of a combination of a -emitting tracer with a radiation detection probe (see3
and references therein). Since radiation can traverse large amounts of tissue, any uptake of the tracer in nearby
healthy tissue represents a non-negligible background, often preventing the usage of this technique.
To mitigate this effect it was suggested in literature the use of b1 decaying tracers4–7. The emitted positrons in
fact have a limited penetration and their detection is local. Nonetheless, positrons annihilate with electrons in the
body and produce s with an energy of 511 keV: the background persists and actually increases in energy. The
improvement with respect to the use of pure emitters is that a dual system can be devised where the background
can be measured separately and subtracted from the observed signal. This approach has been studied in pre-
clinical tests8–12 but it is not yet in use in the clinical practice. The largest limitations range from the time needed to
identify a residual, the dimensions of the probes and the dose absorbed by the medical personnel.
A better solution to the current limits of RGS would be to eliminate the background from radiation. This
study suggests therefore the use of pure b2 radiation that penetrates only a few millimetres of tissue with
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essentially no contamination, being the bremsstrahlung contri-
bution, with a 0.1% emission probability, negligible. Furthermore,
a b2 probe, detecting electrons and operating with lower back-
ground, provides a clearer delineation of margins of the radioactive
tissue, requires administration of a radio-pharmaceutical with a
lower activity and it is smaller and easier to handle in the surgical
environment. The lower absorbed dose, together with the short range
of electrons, implies an almost negligible radiation exposure to med-
ical personnel and therefore a larger number of RGSs per year for the
surgeon.
The idea of detecting b2 emission was first proposed at the very
beginning of the development of RGS13. However, it was soon aban-
doned due to the particular phenomenology of this emission. The
short electron free-path demanded for low invasiveness detectors to
be used intra-operatively in contact with the tissues and sensitive
enough to absorbed dose normally accepted in nuclear medicine.
Both requirements were not satisfied by instruments and materials
available at the time, while are easily reachable with modern
technologies.
In particular, we report on the developments in the field of the
radio-tracers and in the development and test of a specific intra-
operative probe device that make the RGS with b2 decays feasible.
Results
The clinical case. There are several possible applications of this
technique, many of which probably have not yet been thought of.
First, complete removal of tumour is critical for brain tumours,
where a relapse is particularly dangerous and where other RGS
techniques are limited by the high uptake of the brain. Next,
particular attention should be paid to the complete resection of the
main tumour and of infected lymph-nodes in the case of pediatric
tumours where life expectancy is long. Such tumours are typically
abdominal and therefore probe signals are blinded by background
from kidneys, liver and bladder. Finally, there are abdominal
tumours in adults, like non-palpable metastases in liver and
insulinoma, that would profit from RGS.
Testing this novel technique with most of the above-mentioned
clinical cases requires first to identify and test an appropriate b2-
emitting tracer. We then focused on a brain tumor for which such a
tracer already exists. Based on our experience with the Peptide
Receptor Radionuclide Therapy (PRRT)14–16, the meningioma has
been chosen: this brain tumor is particularly receptive to synthetic
somatostatin analogues, such as DOTATOC, that can be labelled
with the b2 emitting 90Y. Furthermore, the same tracer can be
marked with 68Ga, thus allowing for an estimate of uptake prior to
Figure 1 | The radioguided surgery technique (RGS). Steps of the procedure: (1) a radio-labelled tracer is administered to the patient, before the
surgery; (2) the emitting tracer is preferentially taken up by the tumour; (3) after the cancerous bulk removal, the surgeon explores the lesion with a
radiation detecting probe and looks for targeted tumour residuals in real time. The bottom boxes show the effect of the proposed replacement of the
-emitting tracers (a) with electron-emitting tracers (b). Due to the high penetration power of the photons, in the first case a non-negligible background
can be produced by the healthy organs close to the lesion, sometimes preventing the applicability of the technique. To mitigate this effect a shielding or
active veto is applied (see inset of box a) thus making the probes cumbersome. Electrons, instead, provide a clearer delineation of radioactive tissue’s
margins allowing for a simple and compact probe and requiring a smaller radio-pharmaceutical activity. [Figure drawn by S.M. and E.S.C.].
www.nature.com/scientificreports
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surgery with a Positron Emission Tomography (PET) exam. Finally,
it was recently shown that with an appropriate SPECT device also the
brehmsstrahlung emission of the 90Y can be use to verify the
receptivity17.
The b2 detecting probe. As far as the probe design is concerned,
the choice of thematerials and the readout electronics is driven by the
need to maximize the sensitivity to electrons while minimizing the
sensitivity to photons. Para-terphenyl, or p-terphenyl, was adopted
as electron detector after a detailed study18 due to its high light yield
and low density, with consequent low sensitivity to photons.
A first prototype of the b2 probe was developed (see Fig. 2) and
tested with phantoms using 90Y diluted in a physiological saline
solution (see Methods for the experimental set-up and Supple-
mentary Information for more details on the test results). We
explored the range of activity concentration from 22 to 5 kBq/ml
to be compared with the 20 kBq/ml value estimated by analyzing
PET DICOM images obtained administering 3 MBq/kg of 68Ga-
DOTATOC to patients affected by meningioma. We therefore
studied the probe performance close and below the activity range
achieved for diagnostic investigation.
We explored the first prototype response with four phantoms
simulating cancerous residuals with different topologies (see
Supplementary Fig. S1). The 0.1 ml volume phantom, referred to
as ‘‘RESIDUAL’’, has dimensions compatible with residuals well
identified with the nuclear magnetic resonance. To check the effect
of the phantom depth on the probe response and resolution in dis-
tinguishing the residual edge, the other three cylindrical phantoms
have the same activity concentration, footprint (13 mm2) but differ-
ent heights: 1, 2, and 3 mm referred to as ‘‘H1’’, ‘‘H2’’, ‘‘H3’’
respectively.
A 1.5 mm step blind automated scan over the phantom engraved
surface was performed when the activity concentration reached
16 kBq/ml. Even by limiting the acquisition time to 1 s per step
the test demonstrated that all the residuals would be identifiable in
absence of background from nearby organs. The signal from the
tumor residuals was studied at maximum and minimum activity
concentrations, 22 and 5 kBq/ml, and the observed rates are reported
in Tab. 1. The electronic noise was found to be negligible.
Background rates, dominated by the signal coming from the uptake
of nearby healthy tissue, were estimated using a full simulation of the
system with FLUKA program19, based on the above mentioned
DICOM images showing that the nearby healthy tissue uptake is
approximately 10 times smaller than the tumour.
From the signal and background rates, taking into account the
Poisson fluctuations of the measured counts, we computed the
false-positive (FP) and the false-negative (FN) rates for a given time
interval measurement with the probe. We estimated (see Tab. 1) the
time needed to achieve FP< 1% and FN, 5% and found it to be 1 s
for 22 kBq/ml activity concentration and up to 10 s in the case of a
concentration as low as 5 kBq/ml. Further improvements of the
probe are needed to reduce such time at a level compatible with
surgical environment and administer down to 5 kBq/ml.
The effect of an off-axis measurement has been verified bymoving
the probe away from the phantom centre. The test showed that the
rate is reduced by a factor 2 whenmoving the probe 0.5 mm far from
the phantom edge (see Supplementary Fig. S4). This allows us to
conclude that the probe distinguishes the residual edge. This test also
demonstrated the lateral shielding effectiveness of this prototype
making the probe insensitive to electrons coming from the sides
hence increasing the tumor-spotting capability. This test also shows
that the probe is insensitive of long-range radiation that could be
caused by the activity of the 90Y in nearby samples.
Radiation exposure to patient and medical personnel. One of the
key points of this technique is the low irradiation of the patient and
above all of the medical staff. As previously mentioned, we estimated
that a 22 kBq/ml activity concentration, corresponding to admini-
stering approximately 3 MBq/kg, would be more than sufficient for
the technique to be effective.
From Ref. 16 we obtained that the total body dose absorbed by a
70 kg patient after administration of 210 MBq of 90Y-DOTATOC is
approximately 21 mSv, while the effective dose is about 70 mSv. This
Figure 2 | First prototype of the intraoperative b2 probe. The core is a
cylindrical scintillator (diameter 2.1 mm, height 1.7 mm) of poli-
crystalline p-terphenyl. A ring of PVC wraps the scintillator and shields it
against radiation coming from the sides. The device is encapsulated inside
an easy-to-handle aluminum body as protection against mechanical stress
and it is protected against light by a thin PVC layer.
Table 1 | Results of the test on the first probe prototype. The probewas tested on phantoms sized as possible tumour residuals of interest, filled
with 90Y in saline solution to simulate the situation after bulk meningioma removal. The rates measured with two different 90Y activity
concentrations (22 and 5 kBq/ml) are reported (Rate). The minimal acquisition time (T) needed to detect tumour residuals with a false-
negative probability ,5% and a false-positive probability ,1% was estimated extrapolating the laboratory test results to a real case by
means of a detailed simulation
Phantom Diameter (mm) Height (mm) Volume (ml) Rate (cps) 22 kBq/ml T (s) 22 kBq/ml Rate (cps) 5 kBq/ml T (s) 5 kBq/ml
Residual 6 3.5 0.10 31.6 1 6.6 2
H1 4 1 0.01 12.4 2 2.6 .10
H2 4 2 0.02 17.7 1 3.7 4
H3 4 3 0.04 20.1 1 4.2 4
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corresponds to approximately two Computed Tomography (CT)
exams and therefore there is room for improvement in reducing
the required activity.
To evaluate the dose absorbed by the surgeons we simulated a set-
up similar to the common situation of an operating room. Both
activities of neoplastic cells and normal tissue were taken into
account, according to the ratios obtained from the aforementioned
studies on PET images. The equivalent dose absorbed by the sur-
geon’s hands computed for RGSwith a 90Y emitting tracer is expected
to be smaller than 1 mSv/hour. The corresponding value for estab-
lished RGS with 99mTc radio-label tracer is 24 mSv/hour as estimated
with the simulation, which was consistent with Ref. 1. Similarly, the
total-body dose to the surgeon is 0.13 mSv/hourwith theb2RGShere
proposed, to be compared with approximately 6 mSv/hour of the
99mTc RGS.
Discussion
The radio-guided surgery represents a very useful surgical adjunct in
those cases where a complete resection, intended as full enhancing
mass removal, is crucial both for recurrence-free survival and the
overall survival of the patients, particularly for those tumours where
the surgical mass removal is the only possible therapy.
We are proposing a radical change in the paradigm of this tech-
nique: the use of b2 radiation instead of or b1 radiation. The
reduced penetration power of electrons should allow the extension
of this technique to clinical cases that would be otherwise prevented
by the presence of nearby healthy organs taking up the tracer.
This novel approach allows to develop a simple and compact
probe which, detecting electrons and operating with low radiation
background, provides a clearer delineation of margins of radioactive
tissue and requires a smaller radio-pharmaceutical activity to detect
tumour remnants compared to traditional RGS approaches.
Moreover, due to the lower absorbed dose and the short range of
electrons, the radiation exposure to the patient and medical person-
nel becomes almost negligible. Such considerations apply also in the
comparison with the b1 RGS, since in the latter the background is
in any case present, albeit subtracted with the dual-probe approach.
Furthermore, measurements performed in absence of background,
as in the case of the proposed b2 RGS, require by definition shorter
read-out times than measurements with background subtraction.
Finally, the need to duplicate the probe for the background estima-
tion makes b1 probes intrinsically less compact.
We have presented pre-clinical tests of a prototype probe support-
ing the above statements. From these measurements we extrapolated
with a detailed simulation the expected performance with menin-
gioma, representing our test clinical case. Nonetheless, the actual
uptake on the margins of the lesion, the impact of tissue between
the probe and the residual and the effect of the nearby blood is
something to be estimated in clinical tests. Once the feasibility of
such technique will be demonstrated with meningioma, it will be
possible to extend it to other clinically relevant cases, eventually
together with the development of specific radio-tracers.
Methods
The probe prototype. The core of the probe (see Fig. 2) is a cylindrical scintillator
(diameter 2.1 mm, height 1.7 mm) of poli-crystalline para-terphenyl doped by 0.1%
in mass of diphenylbutadiene. Para-terphenyl was adopted, after a detailed study18,
due to its high light yield (3.5 times larger than typical organic scintillators), non-
hygroscopic property and low density. The scintillator is shielding against radiation
coming from the sides by wrapping it with a 7 mm external diameter ring of PVC.
The device is encapsulated inside an easy-to-handle aluminum body, as protection
against mechanical stress, and has a blinding 0.4 mm-thick black PVC front end cap.
The scintillation light is transported to a photo-multiplier tube (PMT, Hamamatsu
H10721-210), through an optical fibre, and read out by a portable custom electronics
with wireless connection to a PC or tablet. This prototype is compatible with a
standard sterile covering of sub-millimetric film for surgical environment. Also the
very low bias required by the PMT, 5 V, makes the device easily portable.
Experimental set-up of the 90Y test. The phantoms are cylindrical vessels, engraved
at a fixed radius on a PMMA (PlexiglassTM) disk mounted on a rotating table, as
shown in supplementary Fig. S1. Their dimensions are listed in Tab. 1 and are known
with a precision of 10 mm.
During the test, the probe was fixed in vertical position over the disk and the
phantoms were moved under the probe by rotating the disk with a step motor,
controlled via PC. The relative position of the sensitive head of the probe and the
phantom was known with a precision of 10 mm. Two probe-disk distances were
studied: 50 and 150 mm. At the optimal working point (PMT gain ,106 and signal
readout threshold of 21 mV), the background rate due to the photo-multiplier tube
dark current and casual events was measured to be 0.2 counts per second (cps). It was
checked to be stable when operating at room-temperature and with ambient light
conditions.
Estimate of false positive and false negative rates. The rate of false positive and false
negative (FP and FN) is computed from the signal (ns) and background (nb, mostly
due to tracer uptake in healthy tissue) rates estimated, for each phantom, as described
in the Results section. For a given value of the probe acquisition time (tdaq), the
number of signal counts from the tumour and the background is distributed
according to a poisson distribution with mean ms 5 nstdaq and mb 5 nbtdaq,
respectively. Given the minimum number of signal counts needed to flag a positive
identification th, FP is computed as the fraction of times the backgroundwould yield a
positive signal:
FP~1{
Xth{1
N~0
Pmb Nð Þ ð1Þ
where Pm Nð Þ indicates the Poisson probability to have N if the mean is m. Similarly
FN is the fraction of times a tumour residual would not yield a signal
FN~
Xth{1
N~0
Pms Nð Þ: ð2Þ
To determine the minimum acquisition time reported in Tab. 1, FN and FP are
computed in a grid of tdaq and th (see Supplementary Fig. S5) and the smallest value of
tdaq for which FN , 5% and FP< 1% is determined.
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